Oticara’s Nasal Steroid Cream Shows Promising Phase II Results for Post-Surgical Chronic Rhinosinusitis

Oticara has reported positive findings from its Phase II trial evaluating a steroid cream optimized for nasal mucosa in patients with persistent chronic rhinosinusitis following endoscopic sinus surgery. The study was presented at the 2025 American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) Annual Meeting & OTO EXPO.

The open-label, multicentre trial enrolled 24 participants, who received a single in-office application under endoscopic guidance using pre-filled syringes. The study met its co-primary endpoints, showing clinically meaningful improvements in Sino-Nasal Outcome Test (SNOT-22) and 4 Cardinal Symptom Score (4CSS). At week three, 4CSS scores improved by 32.6%, with 58.3% of patients meeting responder criteria, while SNOT-22 improvements exceeded the minimum clinically important difference at weeks three, six, and nine.

Physician assessments demonstrated reduced nasal polyp burden and improved Modified Lund-Kennedy Scores, and 91.7% of patients reported symptom improvement. The treatment was well tolerated, with no serious adverse events or notable changes in intraocular pressure or serum cortisol levels.

19-10-2025